Cargando…
Severe Esophagitis and Gastritis from Nivolumab Therapy
Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, howev...
Autores principales: | Boike, Justin, Dejulio, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Gastroenterology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404341/ https://www.ncbi.nlm.nih.gov/pubmed/28459081 http://dx.doi.org/10.14309/crj.2017.57 |
Ejemplares similares
-
Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018) -
Severe steroid refractory gastritis induced by Nivolumab: A case report
por: Vindum, Helene Hjorth, et al.
Publicado: (2020) -
Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
por: Samonis, George, et al.
Publicado: (2022) -
Nivolumab-induced tumour-like gastritis: A case report
por: Cijauskaite, Elena, et al.
Publicado: (2023) -
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
por: Horisberger, Alice, et al.
Publicado: (2018)